Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis

被引：29

作者：

Lin, Li ^{[1
]}

Liu, Yu ^{[2
]}

Chen, Chen ^{[1
]}

Wei, Anhua ^{[2
]}

Li, Wei ^{[2
]}

机构：

[1] Wuhan Asia Gen Hosp, Dept Oncol, Wuhan, Peoples R China

[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2023年 / 14卷

关键词：

immune-related adverse events; clinical efficacy; immune checkpoint inhibitors; meta-analysis; non-small-cell lung cancer; PEMBROLIZUMAB MONOTHERAPY; CHECKPOINT INHIBITORS; NIVOLUMAB; OUTCOMES; SAFETY; TOXICITIES; MANAGEMENT; ANTI-PD-1; VITILIGO; SURVIVAL;

D O I：

10.3389/fphar.2023.1190001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objective: Our study aimed to identify potential correlations between anti-tumor efficacy and immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC).Methods: We conducted a comprehensive search of online electronic databases up to March 2023 to identify any correlations between irAEs and immune checkpoint inhibitor (ICI) efficacy in NSCLC. We used meta-analysis RevMan 5.3 software to calculate pooled results.Results: Our meta-analysis of 54 studies revealed that patients who experienced irAEs achieved a significantly higher objective response rate (p < 0.00001) and longer progression-free survival (PFS) (p < 0.00001) and overall survival (OS) (p < 0.00001) than those who did not experience irAEs. Additionally, patients with =2 irAEs had better PFS, whereas no significant difference was observed between patients with or without squamous cell carcinoma. Subgroup analysis of irAE types indicated that irAEs (thyroid dysfunction and gastrointestinal, skin, or endocrine irAEs) were associated with better PFS and OS. However, no significant differences were observed between patients with pneumonitis or hepatobiliary irAEs.Conclusion: Our study showed that the occurrence of irAEs was a strong predictor of survival efficacy in patients with NSCLC treated with ICIs. Specifically, patients with >= 2 irAEs and those with thyroid dysfunction and gastrointestinal, skin, or endocrine irAEs achieved a better survival benefit.Systematic Review Registration: Website: , Identifier: CRD42023421690

引用

页数：14

共 69 条

[1] Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice [J].

Ahn, Beung-Chul ;

Pyo, Kyoung-Ho ;

Xin, Chun-Feng ;

Jung, Dongmin ;

Shim, Hyo Sup ;

Lee, Chang Young ;

Park, Seong Yong ;

Yoon, Hong In ;

Hong, Min Hee ;

Cho, Byoung Chul ;

Kim, Hye Ryun .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (06) :1613-1623

[2] Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer [J].

Akamatsu, Hiroaki ;

Murakami, Eriko ;

Oyanagi, Jun ;

Shibaki, Ryota ;

Kaki, Takahiro ;

Takase, Eri ;

Tanaka, Masanori ;

Harutani, Yuhei ;

Yamagata, Nao ;

Okuda, Yuka ;

Furuta, Katsuyuki ;

Sugimoto, Takeya ;

Teraoka, Shunsuke ;

Hayata, Atsushi ;

Tokudome, Nahomi ;

Ozawa, Yuichi ;

Mori, Keita ;

Koh, Yasuhiro ;

Yamamoto, Nobuyuki .

ONCOLOGIST, 2020, 25 (04) :E679-E683

[3] Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer [J].

Aso, Mari ;

Toi, Yukihiro ;

Sugisaka, Jun ;

Aiba, Tomoiki ;

Kawana, Sachiko ;

Saito, Ryohei ;

Ogasawara, Takahiro ;

Tsurumi, Kyoji ;

Ono, Kana ;

Shimizu, Hisashi ;

Domeki, Yutaka ;

Terayama, Keisuke ;

Kawashima, Yosuke ;

Nakamura, Atsushi ;

Yamanda, Shinsuke ;

Kimura, Yuichiro ;

Honda, Yoshihiro ;

Sugawara, Shunichi .

ONCOLOGIST, 2020, 25 (03) :E536-E544

[4] Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer [J].

Assi, Hazem I. ;

Kamphorst, Alice O. ;

Moukalled, Nour M. ;

Ramalingam, Suresh S. .

CANCER, 2018, 124 (02) :248-261

[5] Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program [J].

Baldini, Editta ;

Lunghi, Alice ;

Cortesi, Enrico ;

Turci, Daniele ;

Signorelli, Diego ;

Stati, Valeria ;

Melotti, Barbara ;

Ricciuti, Biagio ;

Frassoldati, Antonio ;

Romano, Giampiero ;

Ceresoli, Giovanni Luca ;

Illiano, Alfonso ;

Verderame, Francesco ;

Fasola, Gianpiero ;

Ricevuto, Enrico ;

Marchetti, Paolo ;

Pinto, Carmine ;

Carteni, Giacomo ;

Scotti, Vieri ;

Tibaldi, Carmelo ;

Fioretto, Luisa ;

Giannarelli, Diana .

LUNG CANCER, 2020, 140 :59-64

[6] Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer [J].

Berner, Fiamma ;

Bomze, David ;

Diem, Stefan ;

Ali, Omar Hasan ;

Faessler, Mirjam ;

Ring, Sandra ;

Niederer, Rebekka ;

Ackermann, Christoph J. ;

Baumgaertner, Petra ;

Pikor, Natalia ;

Cruz, Cristina Gil ;

van de Veen, Willem ;

Akdis, Muebeccel ;

Nikolaev, Sergey ;

Laeubli, Heinz ;

Zippelius, Alfred ;

Hartmann, Fabienne ;

Cheng, Hung-Wei ;

Hoenger, Gideon ;

Recher, Mike ;

Goldman, Jonathan ;

Cozzi, Antonio ;

Fruek, Martin ;

Neefjes, Jacques ;

Driessen, Christoph ;

Ludewig, Burkhard ;

Hegazy, Ahmed N. ;

Jochum, Wolfram ;

Speiser, Daniel E. ;

Flatz, Lukas .

JAMA ONCOLOGY, 2019, 5 (07) :1043-1047

[7] Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study [J].

Bjornhart, Birgitte ;

Hansen, Karin H. ;

Jorgensen, Trine L. ;

Herrstedt, Jorn ;

Schytte, Tine .

ACTA ONCOLOGICA, 2019, 58 (07) :953-961

[8] Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab [J].

Bouhlel, Linda ;

Doyen, Jerome ;

Chamorey, Emmanuel ;

Poudenx, Michel ;

Ilie, Marius ;

Gal, Jocelyn ;

Guigay, Joel ;

Benzaquen, Jonathan ;

Marquette, Charles-Hugo ;

Berthet, Jean-Philippe ;

Mouroux, Jerome ;

Schiappa, Renaud ;

Padovani, Bernard ;

Hofman, Paul ;

Otto, Josiane .

BULLETIN DU CANCER, 2020, 107 (09) :946-958

[9] Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients [J].

Campredon, Pauline ;

Mouly, Celine ;

Lusque, Amelie ;

Bigay-Game, Laurence ;

Bousquet, Emilie ;

Mazieres, Julien ;

Caron, Philippe .

PRESSE MEDICALE, 2019, 48 (04) :E199-E207

[10] Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper [J].

Champiat, S. ;

Lambotte, O. ;

Barreau, E. ;

Belkhir, R. ;

Berdelou, A. ;

Carbonnel, F. ;

Cauquil, C. ;

Chanson, P. ;

Collins, M. ;

Durrbach, A. ;

Ederhy, S. ;

Feuillet, S. ;

Francois, H. ;

Lazarovici, J. ;

Le Pavec, J. ;

De Martin, E. ;

Mateus, C. ;

Michot, J. -M. ;

Samuel, D. ;

Soria, J. -C. ;

Robert, C. ;

Eggermont, A. ;

Marabelle, A. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :559-574

← 1 2 3 4 5 6 7 →